Why Some Patients Don’t Qualify for Thyroid Eye Disease (TED) Clinical Trials – And What Can Be Done

Understanding Thyroid Eye Disease (TED) clinical trial eligibility can be complex for patients seeking innovative treatments. This comprehensive guide explores the common reasons why patients may not qualify for TED clinical trials and provides practical solutions for both patients and healthcare providers.

TED clinical trials have strict inclusion and exclusion criteria to ensure patient safety, optimize study results, and meet regulatory standards. While these criteria are necessary, they can inadvertently exclude many potential participants. For TED patients, common reasons for someone to not qualify, or DNQ (Does Not Qualify), include:

• Disease Stage and Severity: Trials often focus on patients at specific stages of TED, such as those with active inflammation versus those in remission. If a patient’s condition doesn’t fit the study’s needs, they might not qualify.
• Other Health Conditions: TED can occur alongside other issues like hyperthyroidism or autoimmune diseases. Patients with complicated health histories may be excluded to avoid risks or confusion in the trial results.
• Current or Past Medications: Using certain drugs, like steroids or immunosuppressants, may disqualify patients. These medications could affect how the study measures the new treatment’s impact.
• Previous Tepezza Use: Many TED trials exclude patients who have previously been treated with Teprotumumab, sold as Tepezza, due to its potential effects on disease progression or response to investigational treatments. Teprotumumab was the first FDA approved drug therapy for TED.
• Timing of Diagnosis: Many trials exclude patients who have already been treated with Tepezza (teprotumumab) because it might influence the disease’s progression or how a new treatment works.
• When You Were Diagnosed: Some studies only accept patients diagnosed within a certain timeframe. Those who’ve had TED for a long time might not meet this requirement. Some studies may allow potential participants to receive TED screenings.
• No Thyroid Condition: If a patient doesn’t have a diagnosed thyroid condition like Graves’ Disease, they may not qualify since these are often key to studying TED.
• Eye Surgeries: Patients who’ve had specific eye surgeries, like orbital decompression, may be excluded to avoid complications or skewed results.

By understanding these common reasons for DNQ, Leapcure can better tailor recruitment efforts to ensure the right patients are matched with appropriate trials. This helps minimize frustration for patients and streamlines the recruitment process for trial sponsors.

The Impact of DNQ on Patients

For TED patients, being disqualified from a trial can be disappointing and discouraging. Many patients view TED clinical trials as a beacon of hope, especially when conventional treatments have failed or caused adverse effects. A DNQ outcome can lead to:

• Loss of Trust: Patients may feel that the trial process is overly restrictive or inaccessible.
• Frustration and Anxiety: The exclusion can exacerbate feelings of helplessness, especially for those actively seeking solutions.
• Reduced Engagement: DNQ patients might hesitate to participate in future trials, further narrowing recruitment pools.

These impacts underscore the importance of clear communication, support, and alternative options for patients who DNQ.

How Leapcure Can Address DNQ Challenges

Leapcure is committed to minimizing DNQ rates while ensuring that trials are conducted safely and effectively. Here’s how we’re working to address this issue:

1. Pre-Screening Precision

Using advanced pre-screening tools and targeted outreach strategies, Leapcure ensures patients are better matched to appropriate trials. By asking detailed questions about disease history, medications (including prior Teprotumumab use), and other factors upfront, we can reduce the likelihood of DNQ and save patients’ time. You can sign up here to have a Leapcure team member reach out to you.

2. Patient-Centered Communication

When patients DNQ, clear and empathetic communication is crucial. Leapcure provides patients with feedback, explaining why they did not qualify and offering guidance on alternative trials or resources. This helps maintain trust and engagement.

3. Expanding Eligibility Criteria

Collaborating with sponsors and trial sites, Leapcure advocates for more inclusive eligibility criteria where possible. For example, relaxing restrictions on prior treatments or extending timelines for diagnosis may increase patient eligibility without compromising trial integrity.

4. Building a Community of Support

Leapcure fosters connections between DNQ patients and support networks, including patient advocacy groups, educational resources, and future trial opportunities. This holistic approach ensures that patients continue to feel valued and supported, even if they don’t qualify for a specific trial.

5. Leveraging Data for Insights

By analyzing DNQ trends, Leapcure helps sponsors understand common barriers and refine future trial designs. For example, if a significant percentage of TED patients are excluded due to prior Teprotumumab use, this insight could inform trial designs that accommodate this subset of patients.

Looking Ahead: Reducing DNQ Rates in TED Trials

TED is a complex disease that demands innovative and inclusive approaches to clinical research. By addressing the underlying reasons why patients DNQ, Leapcure is not only improving trial recruitment but also enhancing the overall patient experience. This aligns with our mission to connect the right patients to the right trials, ultimately accelerating breakthroughs in TED treatment.

Leapcure recognizes that every DNQ patient represents an opportunity to refine recruitment strategies, advocate for more inclusive criteria, and support individuals on their journey toward better health outcomes. By fostering collaboration between patients, sponsors, and trial sites, we aim to create a TED clinical trial landscape that works for everyone.

If you’re interested in learning more about Leapcure’s patient recruitment strategies or want to explore upcoming TED trials, visit our website or reach out to our team. For additional information, check out our blog on Common Questions About Thyroid Eye Disease. Together, we can make a difference in the lives of TED patients and their families.